SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001576885-24-000035
Filing Date
2024-02-01
Accepted
2024-02-01 17:01:23
Documents
4
Period of Report
2024-02-01

Document Format Files

Seq Description Document Type Size
1 FORM 3 wk-form3_1706824872.html 3  
1 FORM 3 wk-form3_1706824872.xml 3 1715
2 EX-24.1 acumen-section16limitedp.htm EX-24.1 3961
3 acumen-section16limitedp001.jpg GRAPHIC 194766
4 acumen-section16limitedp002.jpg GRAPHIC 36690
  Complete submission text file 0001576885-24-000035.txt   326051
Mailing Address 427 PARK ST. CHARLOTTESVILLE VA 22902
Business Address 427 PARK ST. CHARLOTTESVILLE VA 22902 925-368-8508
Acumen Pharmaceuticals, Inc. (Issuer) CIK: 0001576885 (see all company filings)

IRS No.: 364108129 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O ACUMEN PHARMACEUTICALS, INC. 427 PARK ST. CHARLOTTESVILLE VA 22902
Business Address
Doherty James J. (Reporting) CIK: 0002009718 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-40551 | Film No.: 24587777